Affimed N.V (AFMD) a clinical-stage immuno-oncology company, committed to giving patients back their innate ability to fight cancer, has a couple of upcoming clinical trial events this quarter.
The company has 3 drug candidates in clinical testing - AFM24, Acimtamig (AFM13) and AFM28.
AFM24 in combination with Genentech's approved drug Tecentriq (Atezolizumab) is under a phase I/IIa study in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.